Gastroenterology
therapeutic management of Crohn’s disease. Therap Adv Gastroenterol, 15. doi: 10.1177/17562848221078456.
3 Statistics. 2020. St Marks Hospital Foundation. Available at: https://www.
stmarkshospitalfoundation.org.uk/how-we- are-saving-lives/statistics/.
4 Graham, D.B. and Xavier, R.J. 2020. Pathway paradigms revealed from the genetics of inflammatory bowel disease. Nature, 578(7796), 527–539. doi: 10.1038/s41586-020-2025-2.
5 Mathisen, S. 2022. Bitesized Immunology: Immune dysfunction. BSI Immunology. Available at:
https://www.immunology.org/ public-information/bitesized-immunology/ immune-dysfunction/inflammatory-bowel- disease.
6 Irwin, M. and Rosenthal, S.R. 2018. Fact Sheet: News from the IBD Help Center. Crohn’s and Colitis Foundation. Available at: https://www.
crohnscolitisfoundation.org/what-is-ibd/ medication/biosimilars.
7 Carroll, M. 2021. Which biologics can help treat ulcerative colitis (UC)?. Healthline Media. Available at:
https://www.healthline.com/ health/ulcerative-colitis-take-control/beyond- the-biologic#integrin-receptor-antagonists.
8 Buchner, A.M., Schneider, Y. and Lichtenstein, G.R. 2020. Biosimilars in inflammatory bowel disease. American Journal of Gastroenterology, 116(1), 45–56. doi: 10.14309/ ajg.0000000000000844.
9 Patil, S.A. et al. 2022. The Sincerest Form of Flattery? Biosimilars in Inflammatory Bowel Disease. Inflamm Bowel Dis, 1;28(12): 1915-1923. doi: 10.1093/ibd/izac048.
10 Xu, Z., Davis, H.M. and Zhou, H. 2015. Clinical impact of concomitant immunomodulators on biologic therapy: Pharmacokinetics, immunogenicity, efficacy and safety. The Journal of Clinical Pharmacology, 55(S3). doi: 10.1002/jcph.380.
11 National Institute for Health and Care Excellence (NICE). 2019. Ulcerative colitis: management [NG130]. Available at: https://
www.nice.org.uk/guidance/ng130.
12 National Institute for Health and Care Excellence (NICE). 2019. Crohn’s disease: management [NG129]. Available at: https://
www.nice.org.uk/guidance/ng129/chapter/ Recommendations.
13 Lamb, C.A. et al. 2019. British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. Gut, 68(3), s1–s106. doi: 10.1136/ gutjnl-2019-318484.
14 Hendy, P., Hart, A. & Irving, P. 2015. Anti-TNF drug and antidrug antibody level monitoring in IBD: A practical guide. Frontline Gastroenterology, 7(2), 122–128. doi: 10.1136/flgastro-2014-100527.
15 Sparrow, M.P. et al. 2020. Therapeutic drug monitoring of biologics during induction to prevent primary non-response. J Crohn’s Colitis, 14: 542–56. doi: 10.1093/ecco-jcc/jjz162.
16 Fine, S., Papamichael, K. and Cheifetz, A.S. 2019. Etiology and management of lack or loss of response to anti-tumor necrosis factor therapy in patients with inflammatory bowel disease. Gastroenterol Hepatol (NY), 15: 656–65.
17 McNeill, R.P. and Barclay, M.L. 2020. Cost- effectiveness of therapeutic drug monitoring in inflammatory bowel disease. Curr Opin Pharmacol, 55: 41–46. doi: 10.1016/j. coph.2020.09.006.
18 Nigam, G.B. et al. 2020. UK national survey of gastroenterologists’ attitudes and barriers toward therapeutic drug monitoring of anti- TNF therapy in inflammatory bowel disease. Frontline Gastroenterology, 12(1): 22–29. doi: 10.1136/flgastro-2019-101372.
19 Negoescu, D.M. et al. 2019. Proactive vs reactive therapeutic drug monitoring of infliximab in Crohn’s Disease: A cost-effectiveness analysis in a simulated cohort. Inflammatory Bowel Diseases, 26(1): 103–111. doi: 10.1093/ibd/izz113.
20 Syed, N. et al. 2020. Proactive drug monitoring is associated with higher persistence to infliximab and adalimumab treatment and lower healthcare utilization compared with reactive and clinical monitoring. Crohn’s Colitis 360, 2(3):otaa050. doi: 10.1093/crocol/otaa050.
21 Papamichael, K. et al. 2017. Improved long-term outcomes of patients with inflammatory bowel disease receiving proactive compared with reactive monitoring of serum concentrations of infliximab. Clinical Gastroenterology and Hepatology, 15(10):1580-1588.e3. doi: 10.1016/j. cgh.2017.03.031.
22 Vaughn, B.P. et al. 2014. Proactive therapeutic concentration monitoring of infliximab may improve outcomes for patients with inflammatory bowel disease. Inflammatory Bowel Diseases, 20(11): 1996–2003. doi: 10.1097/ mib.0000000000000156.
23 Lyles, J.L. et al. 2020. Effect of a practice- 52
www.clinicalservicesjournal.com I September 2023
wide anti-TNF proactive therapeutic drug monitoring program on outcomes in pediatric patients with inflammatory bowel disease. Inflammatory Bowel Diseases, 27(4): 482–492. doi: 10.1093/ibd/izaa102.
24 Assa, A. et al. 2019. Proactive monitoring of adalimumab trough concentration associated with increased clinical remission in children with Crohn’s disease compared with reactive monitoring. Gastroenterology, 157(4). doi: 10.1053/
j.gastro.2019.06.003.
25 Sánchez-Hernández, J.G. et al. 2020. A 3-year prospective study of a multidisciplinary early proactive therapeutic drug monitoring programme of infliximab treatments in inflammatory bowel disease. British Journal of Clinical Pharmacology, 86(6): 1165–1175. doi: 10.1111/bcp.14229.
26 Papamichael, K. et al. 2019. Proactive therapeutic drug monitoring of adalimumab is associated with better long-term outcomes compared with standard of care in patients with inflammatory bowel disease. Journal of Crohn’s and Colitis, 13(8): 976–981. doi: 10.1093/ ecco-jcc/jjz018.
27 Papamichael, K. et al. 2018. Proactive infliximab monitoring following reactive testing is associated with better clinical outcomes than reactive testing alone in patients with inflammatory bowel disease. Journal of Crohn’s and Colitis, 12(7): 804–810. doi: 10.1093/ecco- jcc/jjy039.
28 Proactive TDM may lead to better outcomes in IBD compared with reactive TDM. 2022. Gastroenterology Advisor. Available at:
https://www.gastroenterologyadvisor.com/ inflammatory-bowel-diseases-ibd/proactive- tdm-may-lead-to-better-outcomes-in-ibd- compared-with-reactive-tdm/.
29 Patel, R.N. et al. 2020. An Indian national survey of therapeutic drug monitoring with anti-tumor necrosis (TNF) medications in inflammatory bowel disease. Indian Journal of Gastroenterology. 39(2): 176–185. doi: 10.1007/ s12664-020-01047-6.
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76
